Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NODAGA-E(c[RGDyK])2
- Development stage
- Phase 2
- Lead developer
- Rigshospitalet
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
68Ga-NODAGA-E(c[RGDyK])2 is a radiopharmaceutical PET imaging agent developed by Rigshospitalet (Copenhagen University Hospital) for the detection of angiogenesis. It consists of the positron-emitting radionuclide gallium-68 chelated by NODAGA and conjugated to a dimeric cyclic RGD peptide, E(c[RGDyK])2. The tracer specifically targets integrin αvβ3, a cell surface receptor that is significantly upregulated on endothelial cells during angiogenesis and on various tumor cells. By binding to these integrins, the tracer allows for the non-invasive visualization and quantification of angiogenic activity, which is a hallmark of cancer growth and metastasis. It has been evaluated in clinical trials for neuroendocrine neoplasms, breast cancer, and ovarian cancer to assess tumor burden and potential response to anti-angiogenic therapies.
- Other names
- 68Ga-NODAGA-E[c(RGDyK)]268Ga-NODAGA-dimeric RGDGallium-68 NODAGA-E(c[RGDyK])2
02
Targets
αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on 68Ga-NODAGA-E(c[RGDyK])2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-NODAGA-E(c[RGDyK])2.